These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1134 related articles for article (PubMed ID: 25499150)

  • 41. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
    Wong JJ; Lau KA; Pinello N; Rasko JE
    Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
    Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
    Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
    McDevitt MA
    Semin Oncol; 2012 Feb; 39(1):109-22. PubMed ID: 22289497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms underlying the heterogeneity of myelodysplastic syndromes.
    Dussiau C; Fontenay M
    Exp Hematol; 2018 Feb; 58():17-26. PubMed ID: 29175473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations.
    Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D
    Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetics of myelodysplastic syndromes: new insights.
    Graubert T; Walter MJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
    Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetics in myelodysplastic syndromes.
    Heuser M; Yun H; Thol F
    Semin Cancer Biol; 2018 Aug; 51():170-179. PubMed ID: 28778402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel t(X;21)(p11.4;q22.12) translocation adds to the role of BCOR and RUNX1 in myelodysplastic syndromes and acute myeloid leukemias.
    Mavridou E; Lema Fernandez AG; Nardelli C; Pierini V; Quintini M; Arniani S; Di Giacomo D; Crescenzi B; Matteucci C; Sambani C; Mecucci C
    Genes Chromosomes Cancer; 2024 Apr; 63(4):e23235. PubMed ID: 38656651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and biological implications of driver mutations in myelodysplastic syndromes.
    Papaemmanuil E; Gerstung M; Malcovati L; Tauro S; Gundem G; Van Loo P; Yoon CJ; Ellis P; Wedge DC; Pellagatti A; Shlien A; Groves MJ; Forbes SA; Raine K; Hinton J; Mudie LJ; McLaren S; Hardy C; Latimer C; Della Porta MG; O'Meara S; Ambaglio I; Galli A; Butler AP; Walldin G; Teague JW; Quek L; Sternberg A; Gambacorti-Passerini C; Cross NC; Green AR; Boultwood J; Vyas P; Hellstrom-Lindberg E; Bowen D; Cazzola M; Stratton MR; Campbell PJ;
    Blood; 2013 Nov; 122(22):3616-27; quiz 3699. PubMed ID: 24030381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
    Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
    PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
    Babushok DV; Bessler M
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SF3B1 mutant myelodysplastic syndrome: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Impact of Epigenetic Modifications in Myeloid Malignancies.
    Venney D; Mohd-Sarip A; Mills KI
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.